Physician profile
Thomas S Yu
NPI 1588844104
$16,136.17
in general payments reported to CMS, 2019-2025
44 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,257 · 2020: $1,554 · 2021: $1,920 · 2022: $2,049 · 2023: $2,942 · 2024: $2,049 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,355.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,239.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,900.31 | 2019-2025 | Linzess |
| Amgen INC. | $1,577.25 | 2019-2025 | Repatha, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $1,190.60 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,182.52 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $1,013.98 | 2019-2022 | |
| Gilead Sciences, INC. | $674.15 | 2019-2023 | |
| Novo Nordisk INC | $559.79 | 2020-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $553.19 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $482.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $406.18 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $369.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $363.72 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $340.40 | 2023-2025 | Austedo Xr, Austedo Xr |
| Abbott Laboratories | $329.62 | 2019-2023 | Freestyle Libre 2 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.